Brookline Capital Markets Comments on MNPR FY2026 Earnings

Monopar Therapeutics Inc. (NASDAQ:MNPR) – Brookline Capital Markets upped their FY2026 EPS estimates for shares of Monopar Therapeutics in a research note issued to investors on Thursday, May 14th. Brookline Capital Markets analyst K. Dolliver now expects that the company will post earnings per share of ($2.88) for the year, up from their previous estimate of ($3.23). The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($4.11) per share.

A number of other analysts have also weighed in on the stock. Wall Street Zen upgraded shares of Monopar Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 9th. BTIG Research restated a “buy” rating and issued a $104.00 target price on shares of Monopar Therapeutics in a research report on Monday, February 23rd. Cantor Fitzgerald restated an “overweight” rating on shares of Monopar Therapeutics in a research report on Wednesday, January 21st. Chardan Capital restated a “buy” rating and issued a $100.00 target price on shares of Monopar Therapeutics in a research report on Monday, March 30th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Monopar Therapeutics in a research report on Tuesday, April 21st. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $107.00.

Monopar Therapeutics Price Performance

Shares of Monopar Therapeutics stock opened at $56.25 on Tuesday. Monopar Therapeutics has a fifty-two week low of $28.40 and a fifty-two week high of $105.00. The firm has a market capitalization of $376.88 million, a P/E ratio of -29.61 and a beta of 1.49. The company’s 50 day moving average price is $56.97 and its two-hundred day moving average price is $65.54.

Monopar Therapeutics (NASDAQ:MNPR) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.87) by $0.41.

Hedge Funds Weigh In On Monopar Therapeutics

Hedge funds have recently bought and sold shares of the company. Ally Bridge Group NY LLC raised its stake in Monopar Therapeutics by 86.6% during the third quarter. Ally Bridge Group NY LLC now owns 64,455 shares of the company’s stock worth $5,264,000 after buying an additional 29,918 shares during the last quarter. AlphaQuest LLC increased its stake in Monopar Therapeutics by 8.5% in the third quarter. AlphaQuest LLC now owns 1,935 shares of the company’s stock valued at $158,000 after purchasing an additional 151 shares in the last quarter. JPMorgan Chase & Co. increased its stake in Monopar Therapeutics by 1,821.0% in the second quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock valued at $69,000 after purchasing an additional 1,821 shares in the last quarter. Meeder Asset Management Inc. bought a new stake in Monopar Therapeutics in the fourth quarter valued at $65,000. Finally, Russell Investments Group Ltd. bought a new stake in Monopar Therapeutics in the third quarter valued at $28,000. Institutional investors own 1.83% of the company’s stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.